相关实验视频

Updated: Jul 16, 2025

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

干白素17和干白素23抑制剂是否与恶性瘤有关? - - 来自国际人口研究的见解

Khalaf Kridin^1,2,3, Mariam Abdelghaffar⁴, Noor Mruwat³

¹Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.

Journal of the European Academy of Dermatology and Venereology : JEADV

|September 21, 2023

概括

与瘤坏死因子抑制剂 (TNFi) 相比,黄素-17抑制剂 (IL-17i) 和黄素-23抑制剂 (IL-23i) 在牛皮患者中显示癌症风险降低. 这些发现对于生物处方决定至关重要.

科学领域:

免疫学免疫学免疫学
皮肤病学皮肤病学
在瘤学瘤学.

背景情况:

与IL-23和IL-17抑制剂的长期癌症风险尚未完全理解.
牛皮患者需要安全有效的生物治疗.

研究的目的:

在接受IL-23抑制剂 (IL-23i) 和IL-17抑制剂 (IL-17i) 治疗的牛皮患者中评估恶性瘤风险.
为了比较这种风险与在治疗的前五年内接受瘤坏死因子抑制剂 (TNFi) 治疗的患者.

主要方法:

进行了一项基于人口的全球性队列研究.
两项分析比较了IL-17i与TNFi的新用户 (每个为15331名患者),以及IL-23i与TNFi的新用户 (每个为5832名患者).

主要成果:

使用IL-17i与降低非霍奇金淋巴瘤,结肠直肠癌,肝胆癌,卵巢癌,黑色素瘤和基底细胞癌的风险有关.
使用IL-23i与非霍奇金淋巴瘤,肝胆癌和基底细胞癌的风险降低有关.
敏感性分析证实IL-17i和IL-23i的恶性瘤风险降低,与以前没有生物药物治疗的患者相比.

结论:

互乐金-17 抑制剂和互乐金-23 抑制剂与几种恶性瘤的风险降低有关.
在为牛皮开处方生物药物之前,这些发现是重要的考虑因素.

更多相关视频

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.